AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued on Friday, January 26th. The firm presently has a $2.50 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price points to a potential upside of 32.98% from the stock’s previous close.
According to Zacks, “AEterna Zentaris Inc. is a biopharmaceutical company focused on endocrine therapy and oncology. Its lead endocrinology program is a Phase 3 trial in benign prostatic hyperplasia (BPH) with cetrorelix, an LHRH antagonist already marketed for in vitro fertilization under the brand name Cetrotide. The lead oncology program is a Phase 2 trial in endometrial and ovarian cancer with AEZS-108, a targeted cytotoxic peptide conjugate. Other lead compounds include ozarelix for BPH and prostate cancer as well as perifosine for multiple cancers. “
Several other equities analysts also recently issued reports on AEZS. Maxim Group set a $4.00 target price on AEterna Zentaris and gave the company a “buy” rating in a research report on Wednesday, January 17th. HC Wainwright set a $3.00 target price on AEterna Zentaris and gave the company a “buy” rating in a research report on Wednesday, November 29th.
AEterna Zentaris (AEZS) opened at $1.88 on Friday. The stock has a market capitalization of $29.43, a price-to-earnings ratio of -1.04 and a beta of 0.60. AEterna Zentaris has a 12-month low of $0.78 and a 12-month high of $3.75.
An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. lifted its position in shares of AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 56,800 shares of the biopharmaceutical company’s stock after acquiring an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 as of its most recent SEC filing. 1.95% of the stock is currently owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY WARNING: “AEterna Zentaris (NASDAQ:AEZS) Upgraded to Buy by Zacks Investment Research” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.dispatchtribunal.com/2018/02/13/aeterna-zentaris-aezs-upgraded-at-zacks-investment-research.html.
AEterna Zentaris Company Profile
Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.
Get a free copy of the Zacks research report on AEterna Zentaris (AEZS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.